Cancer. What an ugly disease.

SmallCapFirm

Biotech Alert: Could This New Nasdaq Profile Be Ready To Make A Serious Name For Itself? Key Details Now

Complete Report Arrives 9:30AM EST Tomorrow

*SMS Sign-up Details Below*

January 30th

SCF Readers,

Cancer. What an ugly disease.

At this point, we all have known at least a few people who have been directly impacted by cancer.

Good news is, there are companies out there aiming to battle cancer into submission.

Cellular immunotherapy is an innovative treatment approach that harnesses the body’s own immune system to fight cancer.

The global cellular immunotherapy market is expected to grow from $2.74Bn in 2020 to $3.59Bn in 2021. The market is expected to reach $6.73Bn in 2025.

image

One company I've been keeping track of is appearing to be making major headway in cellular immunotherapy along with several other interesting health related therapies/treatments.

At 9:30AM EST Monday, you'll receive the complete report.

Before the opening bell arrives, here's a quick taste of what's to come.

New Nasdaq Biotech Idea - 3 Potential Breakout Catalysts

#1. Heading into the weekend, this profile was displaying several oversold leaning technicals and was trading around its 52-week lows.

Could a healthy reversal be right around the corner after a recent downtrend?

#2. The company recently released an end of 2021 business update highlighting its major accomplishments from last year. They believe they are in a great position to carry through with their growth strategy in 2022 and beyond.

As these highlights continue to make the rounds, it could draw serious attention to this under-the-radar company.

#3. This is another low float idea which means that volatility can arise on a daily basis. According to Yahoo Finance, this profile has fewer than 35Mn shares in its float.

Could these 3 potential catalysts provide a breakout spark near term for this Nasdaq biotech idea?

Since you've got a minute, do this:

image

Your full report arrives soon. Be ready.

Sincerely,

Axel Adams

Editor, SCF


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media.